Download PDF
Horm Metab Res 2011; 43(4): 236-240
DOI: 10.1055/s-0031-1271776
Original Basic

© Georg Thieme Verlag KG Stuttgart · New York

Estrogens Modulate RANKL-RANK/Osteoprotegerin Mediated Interleukin-6 Effect on Thyrotoxicosis-related Bone Turnover in Mice

J. Mysliwiec1 , R. Zbucki3 , A. Nikolajuk1 , P. Mysliwiec3 , K. Kaminski4 , Z. Bondyra5 , J. Dadan2 , M. Gorska1 , M. M. Winnicka2
  • 1Department of Endocrinology, Diabetology and Internal Diseases, Medical University of Bialystok, Bialystok, Poland
  • 2Department of General and Experimental Pathology, Medical University of Bialystok, Bialystok, Poland
  • 31st Department of General and Endocrine Surgery, Medical University of Bialystok, Bialystok, Poland
  • 4Department of Cardiology, Medical University of Bialystok, Bialystok, Poland
  • 5Department of Radiology, Medical University of Bialystok, Bialystok, Poland
Further Information

Publication History

received 06.07.2010

accepted 24.01.2011

Publication Date:
17 February 2011 (online)

Also available at
    Permissions and Reprints

Abstract

Interleukin-6 has been shown to cause imbalance between bone resorption and formation in thyrotoxicosis. The aim of the present study was an attempt to estimate the influence of estrogens on thyrotoxicosis-related disturbances in bone turnover in relation to RANKL-RANK/osteoprotegerin system in IL-6 deficient mice. The study was performed on 56, 12–13 weeks old, female mice: C57BL/6J (wild-type; WT) and C57BL/6JIL6–/–Kopf (IL-6 knock-out; IL6KO). The mice were randomly divided into 8 groups with 7 mice in each one: 1. WT controls, 2. IL6KO controls, 3. WT mice with thyrotoxicosis, 4. IL6KO mice with thyrotoxicosis, 5. WT ovariectomized, 6. IL6KO ovariectomized, 7. WT ovariectomized mice with thyrotoxicosis, and 8. IL6KO ovariectomized mice with thyrotoxicosis. Experimental model of menopause was evoked by bilateral ovariectomy carried out in 8–9 weeks old mice. Thyrotoxicosis was induced by intraperitoneal injection of levothyroxine at a dose of 1 μg/g daily over 21 days. The serum levels of TRACP5b, osteocalcin, OPG, and RANKL were determined by ELISA. RANKL serum concentrations were elevated significantly in all groups of ovariectomized mice as compared to respective controls, however, in a minor degree in IL6KO thyrotoxic mice as compared to wild-type animals. Osteoprotegerin serum levels were significantly increased in all thyrotoxic groups of mice except ovariectomized IL6KO animals. To sum up, the results of the present study suggest that IL-6 plays a key role in stimulation of RANKL-RANK/OPG system and this effect is strongly enhanced in conditions of accelerated bone turnover such as thyrotoxicosis and/or estrogen depletion.

Key words

sRANKL - OPG - IL-6 - hyperthyrosis - osteoporosis - IL-6 knock-out mice

References

  • 1 Manolagas SC, Jilka RL. Bone marrow, cytokines and bone remodelling.  N Engl J Med. 1995;  332 305-311
    Google Scholar
  • 2 Pacifici R. Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis.  J Bone Miner Res. 1996;  8 1043-1051
    Google Scholar
  • 3 Roodman GD. Paget's disease and osteoclast biology.  Exp J Hematol. 1996;  27 1229-1241
    Google Scholar
  • 4 Poli V, Balena R, Fattori E, Markatos A, Yamamoto M, Tanaka H, Ciliberto G, Rodan GA, Costantini F. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion.  EMBO J. 1994;  13 1189-1196
    Google Scholar
  • 5 Hayashi M, Rho MC, Enomoto A, Fukami A, Kim YP, Kikuchi Y, Sunazuka T, Hirose T, Komiyama K, Omura S. Suppression of bone resorption by madindoline A, a novel nonpeptide antagonist to gp130.  Proc Natl Acad Sci USA. 2002;  12 14728-14733
    Google Scholar
  • 6 Murphy E, Williams GR. The thyroid and the skeleton.  Clin Endocrinol. 2004;  61 285-298
    Google Scholar
  • 7 Grimnes G, Emaus N, Joakimsen RM, Figenschau Y, Jorde R. The relationship between serum TSH and bone mineral density in men and postmenopausal women: the Tromsø study.  Thyroid. 2008;  18 1147-1155
    Google Scholar
  • 8 Mysliwiec J, Zbucki R, Winnicka M, Sawicki B, Nikolajuk A, Kaminski K, Mysliwiec P, Musial W, Bondyra Z, Walecki J, Gorska M. A crucial role of interleukin-6 in the pathogenesis of thyrotoxicosis-related disturbances of bone turnover in mice.  Horm Metab Res. 2007;  39 1-5
    Google Scholar
  • 9 O’Brien CA, Jilka RL, Fu Q, Stewart S, Weinstein RS, Manolagas SC. IL-6 is not required for parathyroid hormone stimulation of RANKL expression, osteoclast formation, and bone loss in mice.  Am J Physiol Endocrinol Metab. 2005;  289 E784-E793
    Google Scholar
  • 10 Sims NA, Jenkins BJ, Quinn JM, Nakamura A, Glatt M, Gillespie MT, Ernst M, Martin TJ. Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways.  J Clin Invest. 2004;  113 379-389
    Google Scholar
  • 11 O’Brien CA, Gubrij I, Lin SC, Saylors RL, Manolagas SC. STAT3 activation in stromal osteoblastic cells is required for induction of the receptor activator of NF-κB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin D3 or parathyroid hormone.  J Biol Chem. 1999;  274 19301-19308
    Google Scholar
  • 12 Liu XH, Kirschenbaum A, Yao S, Levine AC. Interactive effect of interleukin-6 and prostaglandin E2 on osteoclastogenesis via the OPG/RANKL/RANK system.  Ann N Y Acad Sci. 2006;  1068 225-233
    Google Scholar
  • 13 van Tuyl LH, Voskuyl AE, Boers M, Geusens P, Landewé RB, Dijkmans BA, Lems WF. Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis.  Ann Rheum Dis. 2010;  69 1623-1628
    Google Scholar
  • 14 Sivagurunathan S, Muir MM, Brennan TC, Seale JP, Mason RS. Influence of glucocorticoids on human osteoclast generation and activity.  J Bone Miner Res. 2005;  20 390-398
    Google Scholar
  • 15 Paternoster L, Ohlsson C, Sayers A, Vandenput L, Lorentzon M, Evans DM, Tobias JH. OPG and RANK Polymorphisms Are Both Associated with Cortical Bone Mineral Density: Findings from a Metaanalysis of the Avon Longitudinal Study of Parents and Children and Gothenburg Osteoporosis and Obesity Determinants Cohorts.  J Clin Endocrinol Metab. 2010;  95 3940-3948
    Google Scholar
  • 16 Shevde NK, Bendixen AC, Dienger KM, Pike JW. Estrogens suppress RANK-ligand induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression.  PNAS. 2000;  97 7829-7834
    Google Scholar
  • 17 Shu L, Guan SM, Fu SM, Guo T, Cao M, Ding Y. Estrogen modulates cytokine expression in human periodontal ligament cells.  J Dent Res. 2008;  87 142-147
    Google Scholar
  • 18 Kodama I, Niida S, Sanada M, Yoshiko Y, Tsuda M, Maeda N, Ohama K. Estrogen regulates the production of VEGF for osteoclast formation and activity in op/op mice.  J Bone Mineral Res. 2004;  19 200-206
    Google Scholar
  • 19 Fuller K, Wong B, Fox S, Choi Y, Chambers TJ. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts.  J Exp Med. 1998;  188 997-1001
    Google Scholar
  • 20 Giner M, Montoya MJ, Vázquez MA, Rios MJ, Moruno R, Miranda MJ, Pérez-Cano R. Modifying RANKL/OPG mRNA expression in differentiating and growing human primary osteoblasts.  Horm Metab Res. 2008;  40 869-874
    Google Scholar
  • 21 Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.  Cell. 1998;  93 165-176
    Google Scholar
  • 22 Jimi E, Akiyama S, Tsurukai T, Okahashi N, Kobayashi K, Udagawa N, Nishihara T, Takahashi N, Suda T. Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function.  J Immunol. 1999;  163 434-442
    Google Scholar
  • 23 Blair JM, Zheng Y, Dunstan CR. RANK ligand.  Int J Biochem Cell Biol. 2007;  39 1077-1081
    Google Scholar
  • 24 Bolon B, Carter C, Daris M, Morony S, Capparelli C, Hsieh A, Mao M, Kosteniuk P, Dunstan CR, Lacey DL, Sheng JZ. Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis.  Mol Ther. 2001;  3 197-205
    Google Scholar
  • 25 Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women.  J Clin Invest. 2003;  111 1221-1230
    Google Scholar
  • 26 Han KO, Choi JT, Choi HA, Moon IG, Yim CH, Park WK, Yoon HK, Han IK. The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone.  Clin Endocrinol (Oxf). 2005;  62 349-353
    Google Scholar
  • 27 Rogers A, Saleh G, Hannon RA, Greenfield D, Eastell R. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women.  J Clin Endocrinol Metab. 2002;  87 4470-4475
    Google Scholar
  • 28 Riggs BL, Khosla S, Atkinson EJ, Dunstan CR, Melton 3rd LJ. Evidence that type I osteoporosis results from enhanced responsiveness of bone to estrogen deficiency.  Osteoporos Int. 2003;  14 728-733
    Google Scholar
  • 29 Jorgensen HL, Kusk P, Madsen B, Fenger M, Lauritzen JB. Serum osteoprotegerin (OPG) and the A163G polymorphism in the OPG promoter region are related to peripheral measures of bone mass and fracture odds ratios.  J Bone Miner Metab. 2004;  22 132-138
    Google Scholar
  • 30 Anastasilakis AD, Goulis DG, Polyzos SA, Gerou S, Koukoulis G, Kita M, Avramidis A. Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial.  Horm Metab Res. 2008;  40 281-285
    Google Scholar
  • 31 Lee JS, Ryu CH, Moon NH, Kim SJ, Park SY, Suh KT. Changes in serum levels of receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, IL-6 and TNF-alpha in patients with a concomitant head injury and fracture.  Arch Orthop Trauma Surg. 2009;  129 711-718
    Google Scholar
  • 32 Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women.  J Clin Endocrinol Metab. 2001;  86 631-637
    Google Scholar
  • 33 Schett G, Kiechl S, Redlich K, Oberhollenzer F, Weger S, Egger G, Mayr A, Jocher J, Xu Q, Pietschmann P, Teitelbaum S, Smolen J, Willeit J. Soluble RANKL and risk of nontraumatic fracture.  JAMA. 2004;  291 1108-1113
    Google Scholar

Correspondence

J. MysliwiecMD, PhD 

Department of Endocrinology

Diabetology and Internal

Diseases

Medical University of Bialystok

M.C. Sklodowskiej-Curie 24 A

15-276 Bialystok

Poland

Phone: +48/85/746 82 39

Fax: +48/85/744 76 11

Email: janusz.mysliwiec@umwb.edu.pl

      >